70624-30-5

Usage

Organic compound

As an organic compound, it is primarily composed of carbon atoms along with hydrogen, oxygen, and sulfur atoms, which are common elements in organic molecules.

Carboxylic acid

2-(5-Methylthiophen-2-yl)acetic acid is a carboxylic acid, meaning it contains a carboxyl functional group (-COOH) that contributes to its acidic properties.

Thiophene ring

The presence of a thiophene ring (a five-membered ring with one sulfur atom) in its structure imparts unique chemical properties and reactivity to the compound.

Methyl group

A methyl group (-CH3) is attached to the thiophene ring, which can influence the compound's reactivity, stability, and solubility.

Synthesis of pharmaceuticals and agrochemicals

Due to its potential therapeutic and biological activities, 2-(5-Methylthiophen-2-yl)acetic acid is used in the synthesis of various pharmaceuticals and agrochemicals.

Building block for other organic compounds

The compound serves as a building block in the production of other organic compounds, making it a versatile intermediate in organic synthesis.

Reagent in organic reactions

2-(5-Methylthiophen-2-yl)acetic acid is commonly used as a reagent in organic reactions, which means it can participate in various chemical transformations to produce new compounds.

Precursor for complex molecule synthesis

As a precursor, the compound serves as a starting material for the synthesis of more complex molecules, highlighting its importance in organic synthesis and chemical research.

Upstream product

• 82670-76-6 [1-dimethylamino-2-(5-methylthiophen-2-yl)vinyl]-phosphonic acid diethyl ester 
• 1918-79-2 2-methylthiophene-5-carboxylic acid 
• 13679-70-4 5-methylthiophene-2-carboxaldehyde 
• 13679-74-8 2-Acetyl-5-methylthiophen 

Downstream Products

• 1268444-77-4 (4R)-4-[(2-chlorophenyl)sulfonyl]-N-(1-cyanocyclopropyl)-1-{[1-(5-methylthien-2-yl)cyclopropyl]carbonyl}-L-prolinamide 
• 1268445-12-0 (4R)-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-N-(1-cyanocyclopropyl)-1-{[1-(5-methylthien-2-yl)cyclopropyl]carbonyl}-L-prolinamide 
• 127035-89-6 2,6-Dimethyl-4-[(E)-2-(5-methyl-thiophen-2-yl)-vinyl]-phenol 

Relevant academic research and scientific papers

Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones

A series of azetidin-2-ones substituted at positions 1, 3 and 4 of the azetidinone ring scaffold were synthesised and evaluated for antiproliferative, cytotoxic and tubulin-binding activity. In these compounds, the cis double bond of the vascular targeting agent combretastatin A-4 is replaced with the azetidinone ring in order to enhance the antiproliferative effects displayed by combretastatin A-4 and prevent the cis/trans isomerisation that is associated with inactivation of combretastatin A-4. The series of azetidinones was synthetically accessible via the Staudinger and Reformatsky reactions. Of a diverse range of heterocyclic derivatives, 3-(2-thienyl) analogue 28 and 3-(3-thienyl) analogue 29 displayed the highest potency in human MCF-7 breast cancer cells with IC50 values of 7 nM and 10 nM, respectively, comparable to combretastatin A-4. Compounds from this series also exhibited potent activity in MDA-MB-231 breast cancer cells and in the NCI60 cell line panel. No significant toxicity was observed in normal murine breast epithelial cells. The presence of larger, bulkier groups at the 3-position, for example, 3-naphthyl derivative 21 and 3-benzothienyl derivative 26, resulted in relatively lower antiproliferative activity in the micromolar range. Tubulin-binding studies of 28 (IC50 = 1.37 μM) confirmed that the molecular target of this series of compounds is tubulin. These novel 3-(thienyl) β-lactam antiproliferative agents are useful scaffolds for the development of tubulin-targeting drugs.

Acylaminothiazole derivatives, their preparation and their therapeutic use

Compound corresponding to the general formula (I): in which, X represents an oxygen or sulphur atom; R1 represents a C1-10 alkyl group optionally substituted, a C3-7 cycloalkyl, thienyl, pyridinyl or pyrimidinyl group; the thienyl groups being optionally substituted; the phenyl group being optionally substituted; R2 represents a C1-6 alkyl group optionally substituted, a C3-7 cycloalkyl, piperidinyl, phenyl or pyridinyl group; the C3-7 cycloalkyl and piperidinyl groups being optionally substituted; the phenyl and pyridinyl groups being optionally substituted; R3 represents a hydrogen atom or a C1-6 alkyl group optionally substituted with a C3-7 cycloalkyl group; R4 represents a hydrogen atom or a C1-6 alkyl group; R5 and R5′ represent, independently of each other, a hydrogen or halogen atom, a hydroxyl or C1-3 alkyl group; or R5 and R5′ form together an oxo or oxime group such as: where R7 represents a hydrogen atom or a C1-3 alkyl; n represents an integer ranging from 0 to 3; and R6 represents, independently of each other when n=2 or 3, a hydrogen or halogen atom, a hydroxyl, C1-3 alkyl, C1-3 alkoxy, C1-3 fluoroalkyl or C1-3 fluoroalkoxy group; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. therapeutic application.

Ramoplanin derivatives possessing antibacterial activity

Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

Cyclic ketone derivatives and their medical applications

The present invention relates to cyclic ketones represented by the following formula and to drugs in which an effective component is such a cyclic ketone or a pharmacologically acceptable salt thereof.The cyclic ketones of the present invention encourage the production of blood platelets, leukocytes and erythrocytes, and can be employed in the prevention or treatment of cytopaenia brought about by cancer chemotherapy, radiotherapy or drug therapy, or by immunological abnormality, anaemia and the like.